Navigation Links
Neuland Labs Reports First Quarter Fiscal Year 2014 Financial Results
Date:8/2/2013

HYDERABAD, India, Aug. 2, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year (FY) 2014, ended June 30, 2013.

"Neuland reported continued progress on our campaign to reduce costs and increase profitability in the first quarter," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs. "Our focus on better managing our costs of production and overall expenses resulted in profits that were treble those reported in the comparable quarter of last year, despite the challenges posed by the continued weakness in the Indian rupee."

Revenues for the first quarter of FY 2014 were $20.27 million (1.21 billion INR*) compared to revenues in the first quarter of FY 2013 of $21.15 million (1.27 billion INR), a decrease of 4%.

Neuland reported EBITDA of $3.44 million (206.0 million INR) in the first quarter of FY 2014, compared to EBITDA of $2.60 million (155.71 million INR) in the comparable period in FY 2013, an increase of 32%.

After-tax profits in the first quarter of FY 2014 were $1.31 million (78.11 million INR), compared to after-tax profits of $0.51 million (30.8 million INR) in the first quarter of FY 2013, an increase of 157%.

"Neuland is also making progress on our strategic objective of strengthening our product mix," noted Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs. "We increased product sales more than 10% from the last quarter, and importantly, this growth was concentrated in our higher margin businesses, such as contract manufacturing and new generic APIs, in line with our move to enhance the value of our product mix. Neuland's decades-long record of R&D innovation, quality and regulatory excellence make us well-positioned to continue to increase market share in these high growth, higher margin sectors."

For a complete set of Neuland's FY 2014 and FY 2013 financial data, visit http://neulandlabs.com/about/financials.html.Neuland Laboratories is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the symbol Neuland.EO. 

* = Indian rupees

About Neuland Labs 
For over 25 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in 85 countries.  Neuland Labs has developed more than 300 processes and 60 APIs, and it has filed more than 45 US drug master files (DMFs), 14 EU CEPs and a total of more than 400 DMFs worldwide.  Its manufacturing facilities are inspected and approved by the US FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001. For more information, visit www.NeulandLabs.com.Contacts:Neuland Laboratories Ltd.

U.S. Media

India MediaViswanathan NS

BLL Partners/Brandwidth Solutions

Concept PRChief Financial Officer

Barbara Lindheim

Geeta Fadnavis+91 40 30211600

+1 212 584-2276

+91 98 49256292NSViswanathan@neulandlabs.com

blindheim@bllbiopartners.com

geeta@conceptpr.com


'/>"/>
SOURCE Neuland Laboratories Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Reports Financial Results For Fiscal Year 2013
2. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
3. Neuland Labs Reports Second Quarter Fiscal Year 2013 Financial Results
4. Neuland Labs Reports First Quarter Fiscal Year 2013 Financial Results
5. Neuland Labs Reports Financial Results For Fiscal Year 2012
6. IRIDEX Reports 2013 Second Quarter Results; $9.2 Million Record Q2 Revenue
7. Uroplasty Reports Fiscal First Quarter 2014 Financial Results
8. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities
9. Optimer Reports Second Quarter 2013 Financial Results
10. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
11. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Eisai Inc., ... announced today that it is participating in Access ... non-communicable diseases (NCDs) prevention, treatment and care in ... Accelerated is the first multi-stakeholder, international initiative in ... pharmaceutical companies, including Eisai, in collaboration with the ...
(Date:1/18/2017)... NEW YORK , January 18, 2017 ... perception of people regarding the use of cannabis both for ... not only are more Americans open to the use of ... and financial sectors. According to Arcview Market Research, the North ... 2016, up 30% from the previous year. The research projects ...
(Date:1/17/2017)... Jan. 17, 2017 Precision medicine is ... the treatment of disease. The approach allows doctors ... a therapy. The approach studies the individual profile ... and environment. In January 2015, Precision Medicine Initiative ... all diseases with more than one million volunteers. ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland ... collaborating on a research project focused on multiple sclerosis (MS). Led by Christopher ... nanotechnology to control the disease without compromising normal immune function that often occurs ...
(Date:1/18/2017)... West Palm Beach, FL (PRWEB) , ... January 18, 2017 , ... ... April as a fund raiser for Smile Train, an international charity that provides free ... is a hobby of mine and in the past I have run to support ...
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment to quality ... achieved certification to ISO 13485. This certification is another way they are making constant ... and services that they need. , The ISO 13485 Certification is a major accomplishment ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the ... project with the donation of cochlear implants. In February 2017, the first three ... a fair chance of leading an independent life. This engagement builds on the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... January is National Stalking Awareness Month ... to lurk in the corners and commit the crime of stalking, a very real danger ... addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know it. Name ...
Breaking Medicine News(10 mins):